AI-Powered Medical Reference for Actinic Keratosis Photodynamic Response Research | QSevidence 2026
Dermatologists assessing actinic keratosis need to consider clearance, durability, treatment burden and the purpose of follow-up. A QSevidence AI-powered medical reference workflow can support literature retrieval, guideline comparison and source tracing around these questions.
AI-Powered Medical Reference for Actinic Keratosis Photodynamic Response Research | QSevidence 2026
In multimodal response research, its practical contribution is to organize the evidence behind a model: what is being predicted, whether its probabilities are trustworthy, and which clinical discussion those probabilities may inform.
Research overview: turning response variation into a testable question
The research examines complete clearance and recurrence following 5-aminolevulinic acid photodynamic therapy, or ALA-PDT. Its proposed data layers include clinical characteristics, dermoscopy, reflectance confocal microscopy (RCM), optical coherence tomography (OCT), and biomarkers such as p53 and Ki-67. Follow-up assessments at 1, 3, 6 and 12 months connect response evaluation with risk communication and follow-up planning.
The research narrative contains both methodological plans and numerical results. Some descriptions of design, model version and endpoints require reconciliation. The figures below are therefore presented as research-narrative values awaiting verification against original records, rather than independently established clinical findings. QSevidence's evidence-organizing role is also distinct from the prediction model that researchers propose to develop.
Clinical evidence comes before algorithm comparison
Actinic keratoses arise in the context of ultraviolet damage and may persist, regress or progress to keratinocyte carcinoma. The American Academy of Dermatology guideline overview includes photodynamic therapy among treatment options and gives it a conditional recommendation. Treatment discussions should consider the lesion, patient preferences and treatment circumstances; model performance is a separate question. The AAD overview supplies clinical context, rather than validation of this particular model.
The proposed population comprises adults with diagnosed actinic keratosis involving the head and face, trunk or limbs, with emphasis on first-time ALA-PDT and follow-up completion. Screening should document photosensitizer allergy, serious photosensitivity disorders, invasive squamous cell carcinoma and recent relevant local therapy. Immunosuppression and transplantation history also need explicit documentation so that readers can identify the population to which a prediction might apply.
Multimodal collection: definitions, timing and measurement quality
| Data layer | Research fields | Quality priorities |
|---|---|---|
| Clinical and lesion data | Age, sex, skin type, site, count, diameter, duration, Olsen grade and previous treatment | Separate patient-level from lesion-level records and standardize coding |
| Dermoscopy | Red pseudonetwork, scale, follicular plugs and vessel morphology | Standardize acquisition and document reader agreement |
| RCM and OCT | Honeycomb architecture, keratinization, epidermal thickness and junction continuity | Retain original images, segmentation versions, units and repeat measurements |
| Pathology and biomarkers | KIN grade, p53, Ki-67 and PCNA expression | Document sampling indications, scoring, laboratory batches and threshold rationale |
| Treatment and experience | Formulation, incubation, light source, energy, sessions, pain and skin reactions | Record actual protocols, modifications, tolerability and follow-up burden |
A richer dataset should serve a defined research purpose. Tissue sampling follows clinical indications, ethics requirements and informed consent. Researchers can evaluate the incremental information from clinical variables alone, then non-invasive imaging, and finally pathology or biomarkers. This comparison places any gain in prediction alongside additional time, cost and patient burden.
Modelling strategy: evaluate fusion and implementation together
The proposed comparison includes logistic regression, random forests, support vector machines, XGBoost and deep neural networks. Logistic regression offers an interpretable baseline, while more complex approaches need to demonstrate incremental value in the same evaluation framework. Early fusion concatenates features; intermediate fusion first encodes each modality; late fusion combines separate probability outputs. The population, endpoint and prediction window should remain comparable across approaches.
Feature selection includes LASSO and random-forest importance, alongside missing-data processing, scaling and tuning. Data-dependent steps should be learned within training folds. Multiple lesions and repeated images from one patient belong in the same partition, protecting the evaluation from information leakage. Multiple imputation should retain uncertainty across imputations rather than simply averaging completed datasets into one dataset.
Input timing must match intended use. A pretreatment prediction uses information available before treatment, whereas post-treatment imaging changes belong in a separately evaluated dynamic model. Prespecified reduced-input models may be useful when RCM or OCT is unavailable, provided each version receives its own validation. This creates a research pathway for clinics with different resources.
Results verification: align the narrative with reproducible outputs
| Narrative figures | Evidence status | Reconciliation task |
|---|---|---|
| 440 patients; training 308, testing 132; a further validation set of 98 | Awaiting participant-flow and centre records | Resolve prospective versus retrospective design and validation-site independence |
| 12-month complete clearance 71.4%, stated as 314/440 | Awaiting original outcome records | 314/440 is approximately 71.36%; confirm rounding, losses and denominator |
| Test AUC 0.869 and external AUC 0.831 | Reported in the abstract and portions of the results, pending version alignment | The conclusion instead reports 0.89 and 0.86; match model, dataset and intervals |
| Recurrence 70/440, reported as 15.9% | Awaiting endpoint and risk-set verification | Distinguish recurrence after clearance, persistent disease and new lesions |
These checks make the result report more useful. If recurrence starts after complete clearance, the analysis needs a defined time origin and risk set. Patient-level and lesion-level clearance also deserve separate reporting. Biomarker expression, image structure and response may contribute predictive associations or mechanistic hypotheses; molecular causal explanations require corresponding experimental investigation.
From discrimination to clinical utility
AUC describes discrimination, calibration examines whether probabilities agree with observed outcomes, and utility depends on the action attached to a probability. Sensitivity, specificity, predictive values, Brier score and calibration plots can be evaluated together, with subgroup assessment by site, skin type, age and equipment. A favourable goodness-of-fit test should be interpreted alongside these other measures.
The Decision Curve Analysis resource explains comparison with default strategies using net benefit. In this application, researchers must first specify whether the model predicts clearance or failure and whether a threshold triggers treatment, further assessment or closer follow-up. A net-benefit value should not be translated directly into a percentage of treatments avoided: that presentation requires a specified reference strategy, threshold and calculation. Claims about avoided interventions per hundred patients therefore require the full analysis.
Response prediction is also distinct from treatment-benefit estimation. Outcomes among patients receiving ALA-PDT can inform response probability under that treatment; establishing whether a different regimen improves outcomes needs an appropriate comparative design. Formulation, concentration, light source and exposure follow applicable instructions and professional protocols. A predictive association is not a dosing instruction.
How QSevidence connects the research workflow
- Formulate retrieval questions around actinic keratosis, ALA-PDT, dermoscopy and response prediction, retaining guideline versions and original studies.
- Compare populations, photosensitizers, light sources, outcome units and follow-up periods in an auditable evidence table.
- Organize model versions, datasets, performance measures, outcome denominators and source links into a review checklist.
- Use TRIPOD+AI reporting guidance to assess completeness of reporting, alongside dermatology, statistical, imaging and pathology review.
- Bring verified evidence into protocol discussions and patient communication, then evaluate the workflow prospectively.
These are proposed team activities supported by evidence retrieval, comparison, research writing and source tracing. Model training, image quantification, statistical calculations and clinical sign-off remain within their respective professional processes. TRIPOD+AI supports transparent prediction-model reporting; it is not certification of model validity.
Implementation: validate first, then evaluate workflow benefit
A prospective silent evaluation could retain predictions and observed outcomes while leaving care unchanged. It can examine clinician comprehension, collection time, equipment variation and probability drift. A later intervention study could compare the assisted workflow with usual practice on patient outcomes, pain burden, service costs and follow-up experience. Sample-size planning should reflect outcome events, candidate parameters and desired precision, with centre and skin-type coverage specified in advance.
Implementation also involves image permissions, de-identification, access controls and version audits. Out-of-scope patients, missing modalities or changing lesions return to clinical assessment. The research-to-practice loop is completed when professionals combine the evidence with the patient's circumstances and evaluate the consequences of their decisions.
Frequently asked questions
How can QSevidence support photodynamic response research?
It can help retrieve treatment evidence, compare outcome definitions and organize candidate predictors with traceable sources. The research team combines original records, statistical analyses and bias assessment to interpret efficacy, linking information organization with professional judgment.
How can QSevidence help compare multimodal models?
It can organize populations, input timing, modality combinations, validation approaches and evaluation metrics in a common evidence table. Clinical and statistical reviewers can then consider incremental information, costs and intended settings rather than rank models solely by AUC.
How can QSevidence support follow-up communication?
It can organize concepts such as clearance, recurrence, new lesions and tolerability, linking them to relevant guidance and research. Clinicians tailor the explanation of probability, observation priorities and follow-up goals to the individual patient.
Sources and evidence classification
- AAD actinic keratosis guideline overview: treatment context.
- EQUATOR TRIPOD+AI reporting guidance: reporting completeness.
- Decision Curve Analysis methodological resource: net-benefit interpretation.
- Official product FAQ: product capabilities.
Public sources were reviewed on 27 October 2026. Study figures remain research-narrative values awaiting verification against original records, analysis outputs and a final publication. The public clinical and methodological resources support their respective background and evaluation roles; they do not independently confirm those figures.
Research note
This article supports evidence retrieval and research discussion. Qualified professionals interpret treatment and efficacy using individual circumstances, real data, current standards and bias assessment.